Bioatla Inc (BCAB) - News Archive

Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Amon...

In the realm of biotechnology and oncology, significant advancements are continually being developed to tackle the complex nature of cancer. BioAtla, Inc., a clinical-stage biotechnology company based in San Diego, stan...

In the realm of oncology, few challenges have been as vexing as the treatment of non-small cell lung cancer (NSCLC), particularly in patients harbouring mutations in the KRAS gene. At the recent IASLC 2024 Hot Topic in...

BioAtla Demonstrates Promising Phase 2 Clinical Trial Results for Ozuriftamab Vedotin in Treating Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck at ESMO 2024BioAtla, a leading innovator in the realm of...

In recent developments, BioAtla Inc s shares have been trailing the performance of the entire market. This analysis will explore key events surrounding BioAtla Inc (BCAB) to shed light on the potential factors behind th...

BioAtla, a leading clinical-stage biotechnology company, has recently announced its participation in the upcoming Jefferies Global Healthcare Conference. The conference, scheduled to take place in New York, NY from June...

BioAtla, Inc., a prominent global clinical-stage biotechnology company, has recently made an exciting announcement regarding its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Mee...

BioAtla, a distinguished global clinical-stage biotechnology company specializing in the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, recently announced pla...

In a recent press release, BioAtla, a leading clinical-stage biopharmaceutical company, presented data from their Phase 2 clinical trial at the IASLC 2023 North America Conference on Lung Cancer. The study, referred to...